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1181-124 Statin Promotes Coronary Collateral Circulation and 
Induces the Regression of Left Ventricular Mass in 
Patients With Angina 
Shin-ichiro Miura. Hiroaki Nishikawa, Masahiro Fujino, Bo Zhang, Hidekl Shimomura. 
Hidekazu Arai, Akira Kawamura, Yashihiro Tsuchiya, Kunihiro Matsuo, Keijiro Saku, 
Fukuoka University, Fukuoka, Japan, Fukuoka Tokusyukai Hospital, Fukuoka, Japan 
Background: There is evidence that hydroxymethylglutaryl coenzyme A reductase inhibi- 
tors (statins) promote collateral circulation (CC) in ischemic limbs and induce the regres- 
sion of left ventricular mass (LVM) in animal models. Therefore, we investigated that the 
treatment with statin may associate with the development of coronary CC (CCC) as 
assessed by Rentrop Score (RS) or the regresston of LVM index (LVMI) as assessed by 
echocardiography in patients with angina. 
Methods: The subjects included 304 patients with angina who underwent coronary 
angiography. Study 1: Subjects who received pravastatin with one (iv), two (2V) or three 
(3V) significantly stenosed vessels were defined as cases (n=42), and age, sex and body 
mass index (BMI)-matched controls without statin treatment (n=lOO) were selected. 
Study 2: Those who received pravastatin or simvastatin were defined as cases (n=66), 
and age, sex and BMI-matched controls (n=l27) ware selected. 
Results: Study 1: The cases included a higher percentage of 3V patients with RS>l than 
the controls but there was no difference among 1V and 2V patients, suggesting that sta- 
tin was associated with CCC independent of the number of stenosed vessels. Patients 
with 3V disease who ware treated with statin were most likely (odds ratio:l7.4(4.4-115)) 
to develop CCC. as assessed by a multiple logistic regression analysis. Study 2: The 
cases showed a significant decrease in LVMI (126g/m2) compared to the controls (146gl 
m2). Although the cases had a significantly higher percentage of patients with hyperten- 
sion (HT) and calcium antagonist (Can) treatment than the controls. there was no rela- 
tionship between LVMI and HT or CaA treatment. Although the cases had significantly 
more stenosed vessels than the controls, there was a significant effect of interaction 
between LVMI with statin treatment and the number of stenosed vessels as assessed by 
ANCOVA. 
Conclusions: Treatment with statin was associated with the existence of CCC and the 
regression of LVMI in patients with angina, suggesting that these effects may play a role 
in the pkiotropic effects of stahn and may be beneficial in coronary heart disease. 
1181-125 Statins in General and Atorvastatin in Particular Do Not 
Affect Platelet Inhibition With Clopidogrel During 
Coronary Stenting 
Victor L. Serebruany, Alex I. Malinin, Steven R. Stelnhubl, Kevin P. Callahan, Paul A. 
Gurbel, Sinai Hospital, Johns Hopkins University, Baltimore. MD 
Background: Platelet activation following srent implantation is well documented and 
may affect both short- and long-term clinical outcomes. Clopidogrel is widely used lo pro- 
duce sustained platelet inhibition in order to prevent further ischemic events in pahents 
with atherothrombosis. Certain clinical scenarios exist when treatment with clopidogrel is 
combined with the chronic use of statins. It has been recently reported that some statins, 
and atorvastatin in particular, may selectively interfere with clopidogrel. limiting the ability 
of this ADP-receptor blocker to inhibit platelet function. 
Methods: We analyzed the data from the PRONTO elavix Reduction of New Ihrombus 
Occurrence) trial, which evaluated platelet inhibition produced by loading dose clopi- 
dogral pre- and post-stenting to determine whether the use of statins influence the ability 
of clopidogrel lo inhibit platelets. Platelets were assessed by conventional plasma aggre- 
gometry induced by 5pM ADP and by expression of GP llbillla (CD41 b). and PECAM-1 
(CD31) by whole blood flow cytometry at baseline, at discharge, and at day 5 following 
stem implantation. 
Results: Data from 100 patients were analyzed. Twenty-five patients were treated with a 
stahn, (9 of those patients received atorvastatin) and 75 were not on statin therapy. 
Platelet inhibition by clopidogrel was Identical in all groups, and resulted in 3540% inhibi- 
tion of aggregation, more than 50% reduction of GP Ilb/llla expression, and 40-45% 
reduction of PECAM-1 expression at day 5 when compared with the baseline values. 
These effects were independent of statin use. 
Conclusion: The study results suggest there are no apparent Interactions between clo- 
pidogrel and statIns. 
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856-l Reduced Endothelial Nitric Oxide Synthase Activity and 
Concentration in Umbilical Veins From Maternal 
Cigarette Smokers 
Malene R. Andersen, Line R. Walker, Steen Stender, Gent&e Hospital, University of 
Copenhagen, Hellerup, Denmark 
Background. The study aimed to investigate the effect of maternal cigarette smoking on 
endothelial nitric oxide synthase (eNOS) activity and concentration in the fetal umbilical 
vein, and to relate rhe findings to the size of the newborn. 
Methods. Fourty-four nonsmoking and 30 smoking (average 15 cigarettes/day) women, 
living in a small area just north of Copenhagen, were Included in the study. Umbilical vein 
endothelial cells were isolated Immediately after delivery. The eNOS activity was deter- 
mined in the samples by the conversion of ‘?-L-arginine to “C-L-citrulline, and the 
eNOS concentration by a human eNOS immunoassay. 
Results. The two aroups of women matched for sociodemoaraohlc and clinical charac- _ _ 
teristics. However, nonsmokers had a higher occupational status than smokers (Regis- 
trar General’s social class 2.1+/-0.1 versus 2.6+/-0.1. kO.001). Newborns of smokers 
had a lower weight (g 3396+/-64 versus 3649+/-58, P=O.O14) and a smaller head circum- 
ference (cm 34.1+/-0.3 versus 35.1+/-0.2, P=O.O02) than those of nonsmokers, but simi- 
lar length and abdominal circumference. The eNOS activity in fetal umbilical veins 
exposed to lntrautenne smoking was 40% lower (pmol L-citrullineiminll@ endothelial 
cells 27.1+/-2.2 versus 45.0+/-5.2. kO.006). and the eNOS concentration 32% lower (ng 
eNOS/lC@ endothelial cells 1.7+/-0.2 versus 2.5+1-0.3, P-0.053) than in nonsmokers. 
The eNOS activity was associated with eNOS concentration (r=O.61, P<O.OOl) and the 
newborn weight (r=O.26, P=O.O14). Multiple regression analysis showed that the reduc- 
tion in eNOS activity associated with smoking was reduced by 40% when adjusting for 
eNOS concentration, and the reduction in birth weight by 26% when adjusting for eNOS 
activity. 
Conclusion. The findings suggest that maternal smoking reduces nitric oxide production 
in the fetal circulation. This may contnbute to retarded growth due to the subsequent 
endothelial dysfunction with reduction of dilatory capacity og the vessels. 
2:15 p.m. 
856-2 Tumor Necrosis Factor-a Infusion Impairs Endothelial 
Function and Induces Endothelial and Metabolic Insulin 
Resistance in Humans 
Helena Dominauez Christian Rask-Madsen, Nikolai Ihlemann, Thomas Hermann, Lars 
Kober, Christian Tarp-Pedersen. Gent&e University Hospital, Hellerup, Denmark, Joslin 
Diabetes Center, Harvard University, Boston, MA 
Background: Tumor necrosis factor-alpha (TNF) levels are elevated In patients with 
acute coronary syndrome and in patients with type 2 diabetes. TNF impairs glucose 
uptake in animal models and in vitro. The aim of this study was lo examine whether TNF 
infusion acutely impairs endothelial function and both insulin-stimulated endothelial func- 
tion and glucose uptake in humans. 
Methods: Lean healthy men were studled in the fasting state. Drugs were infused into 
the brachial artery measuring blood flow by venous occlusion plethysmography. Acety- 
choline was used as endothelium-dependent agonist and nitroprusside as endothelium- 
Independent agonist. Each study was based on ihree infusion series given the same day: 
Infusing first the agonist alone, then co-infusing insulin end the agonist and finally co- 
infusing TNF. insulin and the agonist. For control, TNF and insulin were replaced by their 
vehicle in separate groups of volunteers. Glucose uptake was measured as the product 
between the arterial-venous difference of plasma glucose and forearm blood flow and 
expressed in uM [lo0 ml tissue]-’ min.‘. 
Results: There were performed 40 studies. During TNF infusion, local and systemic 
plasma TNF rose from 1.4 to 134+36 ng L” in the perfused arm and lo 6.5+1.4 ng L-’ h 
systemic blood. The flow during maximal acetylcholine stimulation was 12.7+2.3 ml [lo0 
ml tissue].’ min.‘. Insulin co-infuslon enhanced this flow by 22% (p=O.O007). However 
when TNF was co-infused with insulin forearm decreased this flow by 32% to 8.6e2.3 
(p=O.O02) and TNF alone decreased it by 22% (pcO,OOOl). Insulin also enhanced fore- 
arm blood flow during nitroprusside infuston (p<O.OOl) and TNF blunted it (pcO.001). 
Insulin stimulated forearm glucose uptake by 1 .O*O.l (p=O.O2) but this stimulation was 
completely blocked during TNF infusion since glucose uptake changed by -0.2*0.3 
(p=o.5) 
Conclusion: TNF Infused in humans blunts endothelial function and both insulin-stimu- 
lated endothelium-dependent vasodllatation and glucose uptake. 
2:30 p.m. 
856-3 Tumor Necrosis Factor-a Impairs Endothelium- 
Dependent Vasodilatation and Stimulates Local Tissue 
Plasminogen Activator Release in Humans: Diverse 
Vascular Actions of a Pleiotroplc Cytokine 
Stanley Chia. Motaz Qadan, Richard Newton, Chnstopher A. Ludlam, Keith A. Fox, 
David E. Newby, University of Edinburgh, Edinburgh, United Kingdom, Royal Infirmary of 
Edinburgh, Edinburgh, United Kingdom 
Background: Systemic and vascular inflammation contribute lo the pathogenesis of car- 
diovascular disease, potentially through the actions of pro-inflammatory cytokines. The 
studv aims were to assess the direct effects of local intraarterial tumor necrosis factor-a 
(TN&a), interleukin-6 (IL-6) and endotoxin on blood flow and endogenous tissue plasmi- 
nooen activator (t-PA) release in viva In man. Methods: In a double-blind randomized 
placebo-controlled trial, blood flow, plasma cytokine and flbrinolytic factors concentra- 
tions were determined in both forearms of healthy male subjects using venous occlusion 
plethysmography and blood sampling. Ten subjects received intra-brachial infusions of 
TNF-a (80 or 240 nglmin). IL-6 (30 nglmin), en&toxin (100 pglmin) or saline placebo. 
Eight further subjects received intra-brachial infusion of bradykinin (0.1-I nmollmin), ace- 
tylcholine (5.20 pglmin) and sodium nitroprusstde (2-6 pglmin), two hours after pre-treat- 
ment with TNF-a (60 ngimin) or saline placebo. Results: Plasma TNFa concentrations 
Increased to 539*71 and 1164*41 pg/mL during TNFa 60 ng and 240 ng infusion 
(PcO.001). TNF-a, but not IL-6. endotoxin or placebo, caused a slow onset and marked 
Increase in plasma t-PA antigen and activity concentrations in the infused arm (21.1&X8 
ng/mL and 17.7e4.1 IU/mL, PcO.001) that was sustained for 4 hours. This occurred with- 
out an effect on blood flow but was associated with a rise in plasma IL-6 concentrations 
(PcO.05). Compared to placebo, TNF-a pre-treatment impaired endothelium-dependent 
